Back to Search
Start Over
Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase.
- Source :
-
Circulation [Circulation] 2014 Jan 28; Vol. 129 (4), pp. 451-62. Date of Electronic Publication: 2013 Nov 04. - Publication Year :
- 2014
-
Abstract
- Background: β1-2-adrenergic receptors (AR) are key regulators of cardiac contractility and remodeling in response to catecholamines. β3-AR expression is enhanced in diseased human myocardium, but its impact on remodeling is unknown.<br />Methods and Results: Mice with cardiac myocyte-specific expression of human β3-AR (β3-TG) and wild-type (WT) littermates were used to compare myocardial remodeling in response to isoproterenol (Iso) or Angiotensin II (Ang II). β3-TG and WT had similar morphometric and hemodynamic parameters at baseline. β3-AR colocalized with caveolin-3, endothelial nitric oxide synthase (NOS) and neuronal NOS in adult transgenic myocytes, which constitutively produced more cyclic GMP, detected with a new transgenic FRET sensor. Iso and Ang II produced hypertrophy and fibrosis in WT mice, but not in β3-TG mice, which also had less re-expression of fetal genes and transforming growth factor β1. Protection from Iso-induced hypertrophy was reversed by nonspecific NOS inhibition at low dose Iso, and by preferential neuronal NOS inhibition at high-dose Iso. Adenoviral overexpression of β3-AR in isolated cardiac myocytes also increased NO production and attenuated hypertrophy to Iso and phenylephrine. Hypertrophy was restored on NOS or protein kinase G inhibition. Mechanistically, β3-AR overexpression inhibited phenylephrine-induced nuclear factor of activated T-cell activation.<br />Conclusions: Cardiac-specific overexpression of β3-AR does not affect cardiac morphology at baseline but inhibits the hypertrophic response to neurohormonal stimulation in vivo and in vitro, through a NOS-mediated mechanism. Activation of the cardiac β3-AR pathway may provide future therapeutic avenues for the modulation of hypertrophic remodeling.
- Subjects :
- Angiotensin II adverse effects
Angiotensin II pharmacology
Animals
Cells, Cultured
Cyclic GMP physiology
Cyclic GMP-Dependent Protein Kinases physiology
Disease Models, Animal
Heart Ventricles physiopathology
Humans
Hypertrophy chemically induced
Hypertrophy pathology
Hypertrophy physiopathology
In Vitro Techniques
Isoproterenol adverse effects
Isoproterenol pharmacology
Male
Mice
Mice, Transgenic
Myocytes, Cardiac pathology
Myocytes, Cardiac physiology
Neurotransmitter Agents adverse effects
Receptors, Adrenergic, beta-3 genetics
Signal Transduction physiology
Ventricular Remodeling physiology
Heart Ventricles pathology
Myocytes, Cardiac metabolism
Neurotransmitter Agents pharmacology
Nitric Oxide Synthase physiology
Receptors, Adrenergic, beta-3 metabolism
Ventricular Remodeling drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4539
- Volume :
- 129
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Circulation
- Publication Type :
- Academic Journal
- Accession number :
- 24190960
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.113.004940